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Lehigh Valley Health Network, Allentown, Pennsylvania
Table 1 - Genetic and Clinical Characteristics of MODY Subgroups

BACKGROUND
Genetics

•	Diabetic ketoacidosis (DKA) occurs when the body’s requirements for insulin are higher than the insulin available for use,
resulting in lipolysis, ketogenesis, and ketoacidosis
•	DKA is classically associated with Type 1 diabetes mellitus (DM), but can occur in any patient with diabetes
•	Euglycemic DKA is defined by ketosis, metabolic acidosis, and a blood glucose level less than 200 mg/dL
•	Euglycemic DKA is concerning as it can be easily misdiagnosed and mistreated
• Few cases have demonstrated a possible relationship between empagliflozin and euglycemic DKA
•	Empagliflozin is a sodium glucose co-transporter (SLGT-2) inhibitor in the proximal convoluted tubule of the kidney to reduce
reabsorbed filtered glucose, resulting in decreased serum glucose levels.

Prevalence
Severity
Onset
Microvascular Complications
Treatment

MODY 2

MODY 3

MODY 4

MODY 5

HNF-4α (20q13)

Glucokinase (7p15)

HNF-1α (12q24)

IPF-1 (13q12)

HNF-1ß (17cen-q21)

5%

15%

70%

< 1%

2%

Progressive IGT

Mild,stable
hyperglycemia

Progressive IGT

Progressive IGT

Progressive IGT

12-35 years

Birth

12-28 years

14-40 years

12-28 years

+

Rare

+

+

+renal

Progressive need

Pregnancy

Progressive need

Progressive need

Progressive need

DISCUSSION

CASE PRESENTATION
42 year old female with mature onset diabetes of the young (MODY) type 2
presented to the emergency room with complaints of nausea, vomiting and
epigastric abdominal pain worsening over four days. She was diagnosed
with gestational DM at age 34 and post-partum was unsuccessfully treated
with a variety of oral medications. She underwent testing which revealed a
glucokinase mutation consistent with MODY type 2. Recently, she was started
on empagliflozin-linagliptin in addition to a diet of less than 60 grams of
carbohydrates per day. On admission, imaging was unrevealing, and she was
diagnosed with gastroenteritis. Her serum glucose was 106 mg/dL, potassium
was 4.6 mmol/L, bicarbonate was 21 mmol/L, anion gap was 14, and lipase
was normal. Urinalysis revealed glucose of 500 mg/dL, ketones > 160 mg/dL,
and specific gravity >1.030. Venous blood gas revealed metabolic acidosis. Beta
hydroxybutyrate was 2.71 mmol/L. The patient was diagnosed with euglycemic
DKA. Endocrinology discontinued empagliflozin, emphasizing that the only
treatment required for MODY type 2 is diet restriction. Her symptoms improved,
labs normalized, and she was discharged.
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Figure: Demonstration of the cascade of clinical events and metabolic
changes that contribute sequentially to progressive clinical deterioration
and develoment of full-blown episodes of euDKA. BG, blood glucose; CHO,
carbohydrate; TGs, triglycerides.

•	This case demonstrates a deadly combination of inappropriate SGLT-2 inhibitor use causing decreased serum glucose levels in a
MODY type 2 patient resulting in euglycemic DKA
•	MODY Type 2 results from a defective glucokinase enzyme, therefore increased serum glucose levels are required to trigger insulin
secretion
•	Patients with MODY Type 2 often present with mild fasting hyperglycemia, which is required to stimulate insulin secretion
•	In this case, empagliflozin resulted in decreased serum glucose and increased glucosuria. As a result, the body’s demands for insulin
were higher than the amount of insulin being secreted due to defective glucokinase enzyme, inducing DKA.
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